Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from respiratory syncytial virus (RSV) in a market dominated by Beyfortus, a ...

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Merck & Co., Inc. stands third among them. Merck & Co., Inc. (NYSE:MRK), a global leader in pharmaceuticals ...

Called Enflonsia and developed by Merck & Co., the drug is an antibody intended to prevent illness from RSV, which can be particularly severe in young children.

Merck plans to launch Enflonsia in the United States ahead of the upcoming 2025-26 RSV season and expects ordering for the shots to start next month. Per a Reuters article, Merck will price the ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.

Merck's monoclonal antibody, called clesrovimab and branded as Enflonsia, is the first and only preventive shot that can be administered as a single dose regardless of birth weight in healthy pre ...

Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more Drugmakers met with Trump officials about lowering drug prices but no commitments were made ...

Today's biotech news includes Merck's RSV antibody getting FDA clearance, Bob Nelsen's manufacturing brainchild winding down, etc.